Related coverage linked through entity extraction aliases.
May 05, 2026
Healthcare AI companies are making bold claims, but many have not brought treatments to market. One article said human testing remains the key measure, citing trial timelines, costs, and current programs.
Apr 13, 2026
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Apr 02, 2026
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
Mar 29, 2026
InSilico Medicine and Eli Lilly have entered a major AI drug discovery collaboration potentially worth $2.75 billion, with Lilly gaining exclusive rights to develop preclinical oral therapies. InSilico will receive $115 million upfront plus milestone payments and royalties. The deal reflects increasing pharmaceutical industry adoption of AI platforms to accelerate drug development.
Mar 19, 2026
Insilico Medicine announced a partnership with China Medical System Holdings for AI-powered drug discovery and nominated ISM5059, an NLRP3-targeted drug candidate, for preclinical development following recent FDA IND approval for another AI-created drug.
Mar 19, 2026
Global pharmaceutical R&D deal values surged 49% to $86.7 billion in 2025 as companies concentrate investments in AI-powered drug discovery platforms, with average deal sizes reaching a record $1.16 billion despite fewer total partnerships.
Mar 04, 2026
Insilico Medicine has formed a strategic partnership with Liquid AI to develop lightweight scientific foundation models for drug discovery and entered a drug development collaboration with China Medical System Holdings targeting CNS and autoimmune diseases.
Feb 18, 2026
Insilico Medicine and Memorial Sloan Kettering Cancer Center have entered a collaborative research agreement to discover new therapeutic targets for gastroesophageal malignancies using AI-powered platforms and extensive multi-omic clinical datasets.
Feb 13, 2026
Artificial intelligence is accelerating drug discovery from molecule screening to clinical trials, but legal uncertainty over patent ownership and profit distribution threatens to slow progress as the technology reshapes pharmaceutical development.
Feb 13, 2026
China Medical System Holdings partnered with Insilico Medicine on AI-powered drug discovery in early February 2026 and received Chinese regulatory approval to begin human trials for complement factor B inhibitor CMS-D017.
Dec 29, 2025
Artificial intelligence emerged as the dominant topic in clinical research during 2025, with applications spanning operational efficiency, drug discovery, and patient recruitment, though no AI-discovered drug has yet achieved FDA marketing approval.
Feb 25, 2025
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.
